Komori
Astellas Pharma (4503) · InitiativeFirst stated

Discontinuation of ASP2802 development

First written in FY2025. . Latest entry: FY2025.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Discontinuation of ASP2802 developmentA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2025First statedAnnual report

    「2025年２月　CD20陽性B細胞リンパ腫を対象とする細胞医療ASP2802の開発を中止したことを公表しました。」

    細胞医療ASP2802について、CD20陽性B細胞リンパ腫を対象とする開発中止を初めて記載した。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Astellas Pharma's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.